Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement?
Introduction: Selective monoamine oxidase-B (MAO-B) inhibitors are currently used as coadjuvants for the treatment of early motor symptoms in Parkinson’s disease. They can, based on their chemical structure and mechanism of inhibition, be categorized into reversible and irreversible agents. Areas covered: This review provides a comprehensive update on the development state of selective MAO-B inhibitors describing the results, structures, structure–activity relationships (SARs) and Medicinal chemistry strategies as well as the related shortcomings over the past five years.